Induced Pluripotent Stem Cell

The FDA cleared an investigational new drug application for FT819, a chimeric antigen receptor T-cell therapy for the treatment of CD19-positive tumors, according to a press release from the agent’s manufacturer.

Men receiving androgen-deprivation therapies for hypogonadism often had elevated risk for QT prolongation and torsades de pointes, which confer heightened sudden death odds, researchers reported in Circulation.